Drug intelligence / Profile preview

EX110

Development stage: Preclinical
Lead developer: Excelmab
Modality: Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Subcutaneous, Intravenous

Overview

EX110 is a preclinical-stage trispecific antibody being developed by Guangzhou Excelmab. As of 2024, the specific molecular targets and therapeutic indications for EX110 have not been publicly disclosed by the company. It is part of a broader pipeline of multi-specific antibodies generated using Excelmab's proprietary engineering platforms, which aim to create next-generation biologics with improved binding properties and therapeutic windows for the treatment of cancer or other immune-related conditions.

Targets

DLL3 (Delta-like ligand 3)CD3 (T-cell surface glycoprotein CD3)

Beyond the preview

Go deeper on EX110.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EX110.

Explore the full profile